<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02806713</url>
  </required_header>
  <id_info>
    <org_study_id>H00008816</org_study_id>
    <nct_id>NCT02806713</nct_id>
  </id_info>
  <brief_title>The Effect of Oral PhenazopyrIdine on Perioperative Voiding After Mid-urethral sliNg (EPIPhANy Study)</brief_title>
  <acronym>EPIPhANy</acronym>
  <official_title>The Effect of Oral phenazopyrIdine on Perioperative Voiding After Mid-urethral Sling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized clinical trial using phenazopyridine to decrease voiding dysfunction after a
      retropubic midurethral sling operation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design and randomization This study is a randomized controlled trial. Randomization
      will be performed using software and a block randomization scheme. Study assignment will be
      completed using sequentially numbered sealed opaque envelopes. All the research procedures
      described other than the use or not of phenazopyridine will be applicable to both arms of the
      study. Subjects will have a 50% chances of getting either phenazopyridine or nothing.

      Because pyridium turns the urine orange, it is impossible to blind the patients and
      researchers to the study assignment. Because there is no known placebo that turns the urine
      orange, there is no value to using an actual placebo tablet. Subjects will be assigned to
      either receive pyridium or not receive pyridium preoperatively.

      Screening potential subjects: Investigators will screen potential subjects for
      contraindications to methylene blue. Prior obtaining the routine surgical consent for the
      potential subject's surgical procedure, the patient's medical history in the UMass Electronic
      Medical Record is routinely reviewed. The medical record will be reviewed for a diagnosis of
      G6PD and if found, the potential subject will be excluded.

      Once written consent has been obtained, subject number will be assigned and the appropriate
      randomization envelope will be opened. The study assignment will not be formally shared with
      the subject. Those assigned to the &quot;pyridium&quot; arm will have orders written for the standard
      200 mg dose of pyridium to be given on arrival to the Surgical Admissions Care Unit (SACU).
      Those assigned to the &quot;NO pyridium&quot; arm with have their routine preoperative orders written
      along with an order for &quot;No preoperative pyridium&quot;.

      Subjects will then follow the routine perioperative care for their procedures with the only
      study interventions being the gathering of PHI and performing postoperative pain assessments.

      PHI will be obtained at the time of the surgical consent with the purpose to evaluate for
      possible confounders affecting the postoperative bladder function.

      Surgical procedure:

      The Mid Urethral Sling will be performed in standard fashion based on manufacturer's
      recommendations and instructions to minimize inter-observer variations. We will perform the
      procedure according to our usual and customary techniques. The subject will receive the same
      technique and interventions that a routine patient on the Urogyn service would expect to
      undergo. There will be no changes to the technique for the purpose of the study.

      Bladder challenge:

      Patient will undergo voiding trial at same day surgery per our usual and customary protocol.
      This is the same protocol the subject would undergo as a patient on the Urogyn service. The
      bladder challenge will be interpreted in our usual manner and the subject managed according
      to our routine clinical protocols.

      Postoperative care:

      Subjects will undergo routine postoperative care and followup. Subjects failing their bladder
      challenge will be seen in the Urogyn clinic according to routine clinical protocols and data
      concerning their void trials collected. Subjects will undergo routine followup evaluation 6
      weeks postoperatively in the order to assess any potential long-term voiding dysfunction.
      Information on any postoperative complications will be collected

      Administration of Visual analog scale:

      (1) Visual analog scale for assessment of pain will be administered at two- time intervals.

        1. VAS #1) Preoperative VAS will be done by the principal investigator or any of the study
           assistants. The VAS form will be part of subject's packet.

        2. VAS#2) VAS will be administered by one of the study investigators 2 to 3 hours after the
           surgical procedure in the SACU.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Failed Voiding Trial</measure>
    <time_frame>Postoperatively, up to 3 days after surgery</time_frame>
    <description>Number of participants with a failed postoperative voiding trial. A failed voiding trial is defined as not voiding all urine in 20 minutes or voiding less than 1/3 of total volume (voided volume + post void residual). Patients will undergo voiding trial at same day surgery per the following protocol. Participants who do not pass the voiding trial the same day of their surgical procedure return to the clinic in 3 days to repeat it, following the same protocol described above.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Participant-reported Pain From Pre to Post Procedure Using the Visual Analog Scale (VAS)</measure>
    <time_frame>Preoperatively and then 2 to 3 hours after surgery</time_frame>
    <description>To determine if the phenazopyridine has an analgesic effect after the retropubic midurethral slings, participants will be asked to self-report pain intensity preoperatively and then postoperatively (2 to 3 hours post procedure) using the Visual Analog Scale (VAS). The scale of the VAS is from 0 meaning &quot;no pain&quot; to 10 indicating the &quot;worst pain.&quot; The resulting change is measured as the difference between the self-reported preoperative pain score and the postoperative pain score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Dysfunctional Voiding</condition>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>no phenazopyridine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients not receiving phenazopyridine (standard of care)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>phenazopyridine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving phenazopyridine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenazopyridine</intervention_name>
    <arm_group_label>phenazopyridine</arm_group_label>
    <other_name>Pyridium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no Phenazopyridine</intervention_name>
    <description>Because the obvious effects on the urine coloration of pyridium no placebo or dummy are provided</description>
    <arm_group_label>no phenazopyridine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Any female subjects scheduled to undergo Mid-Urethral Sling (MUS) through the UMass
        urogynecology service for incontinence.

        Exclusion Criteria:

          1. Planned concurrent prolapse or other procedure besides cystoscopy

          2. Using intermittent self catheterization preoperatively

          3. Undergoing spinal anesthesia for the procedure

          4. Known allergy to phenazopyridine (AKA Pyridium)

          5. Renal insufficiency

          6. Any condition or situation that in the attending physician's opinion would
             contra-indicate the use of phenazopyridine

          7. Subjects not competent to give consent

          8. Prisoners

          9. Non-English speaking patients

         10. Age &lt;18

         11. Pregnant patients

         12. Contraindications to the use of IV methylene blue including

               1. Patients with known hypersensitivity reactions

               2. Severe renal insufficiency

               3. Patients with G6PD deficiency
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael K Flynn, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Massachusetts, Worcester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Umass Memorial</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nilsson CG, Kuuva N, Falconer C, Rezapour M, Ulmsten U. Long-term results of the tension-free vaginal tape (TVT) procedure for surgical treatment of female stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2001;12 Suppl 2:S5-8.</citation>
    <PMID>11450979</PMID>
  </reference>
  <reference>
    <citation>Nilsson CG, Palva K, Rezapour M, Falconer C. Eleven years prospective follow-up of the tension-free vaginal tape procedure for treatment of stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2008 Aug;19(8):1043-7. doi: 10.1007/s00192-008-0666-z. Epub 2008 Jun 6.</citation>
    <PMID>18535753</PMID>
  </reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>April 29, 2016</study_first_submitted>
  <study_first_submitted_qc>June 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <results_first_submitted>September 5, 2018</results_first_submitted>
  <results_first_submitted_qc>January 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2019</results_first_posted>
  <last_update_submitted>January 11, 2019</last_update_submitted>
  <last_update_submitted_qc>January 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Michael Flynn</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 7, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT02806713/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>no Phenazopyridine</title>
          <description>Patients not receiving phenazopyridine (standard of care)
no Phenazopyridine: Because the obvious effects on the urine coloration of pyridium no placebo or dummy are provided</description>
        </group>
        <group group_id="P2">
          <title>Phenazopyridine</title>
          <description>Patients receiving phenazopyridine
Phenazopyridine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Urethral injury during procedure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>cancelled surgery</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>we started with 46 subjects per arm, 2 cancelled surgery and 1 had an intraoperative urethral injury.</population>
      <group_list>
        <group group_id="B1">
          <title>no Phenazopyridine</title>
          <description>Patients not receiving phenazopyridine (standard of care)
no Phenazopyridine: Because the obvious effects on the urine coloration of pyridium no placebo or dummy are provided</description>
        </group>
        <group group_id="B2">
          <title>Phenazopyridine</title>
          <description>Patients receiving phenazopyridine
Phenazopyridine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="88"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.7" spread="9.4"/>
                    <measurement group_id="B2" value="49.7" spread="12.6"/>
                    <measurement group_id="B3" value="48.7" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.7" lower_limit="35" upper_limit="68"/>
                    <measurement group_id="B2" value="49.7" lower_limit="37" upper_limit="61"/>
                    <measurement group_id="B3" value="48.7" lower_limit="35" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Failed Voiding Trial</title>
        <description>Number of participants with a failed postoperative voiding trial. A failed voiding trial is defined as not voiding all urine in 20 minutes or voiding less than 1/3 of total volume (voided volume + post void residual). Patients will undergo voiding trial at same day surgery per the following protocol. Participants who do not pass the voiding trial the same day of their surgical procedure return to the clinic in 3 days to repeat it, following the same protocol described above.</description>
        <time_frame>Postoperatively, up to 3 days after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>no Phenazopyridine</title>
            <description>Patients not receiving phenazopyridine (standard of care)
no Phenazopyridine: Because the obvious effects on the urine coloration of pyridium no placebo or dummy are provided</description>
          </group>
          <group group_id="O2">
            <title>Phenazopyridine</title>
            <description>Patients receiving phenazopyridine
Phenazopyridine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Failed Voiding Trial</title>
          <description>Number of participants with a failed postoperative voiding trial. A failed voiding trial is defined as not voiding all urine in 20 minutes or voiding less than 1/3 of total volume (voided volume + post void residual). Patients will undergo voiding trial at same day surgery per the following protocol. Participants who do not pass the voiding trial the same day of their surgical procedure return to the clinic in 3 days to repeat it, following the same protocol described above.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Passed the voiding trial</title>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Failed a voiding trial</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Participant-reported Pain From Pre to Post Procedure Using the Visual Analog Scale (VAS)</title>
        <description>To determine if the phenazopyridine has an analgesic effect after the retropubic midurethral slings, participants will be asked to self-report pain intensity preoperatively and then postoperatively (2 to 3 hours post procedure) using the Visual Analog Scale (VAS). The scale of the VAS is from 0 meaning &quot;no pain&quot; to 10 indicating the &quot;worst pain.&quot; The resulting change is measured as the difference between the self-reported preoperative pain score and the postoperative pain score.</description>
        <time_frame>Preoperatively and then 2 to 3 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>no Phenazopyridine</title>
            <description>Patients not receiving phenazopyridine (standard of care)
no Phenazopyridine: Because the obvious effects on the urine coloration of pyridium no placebo or dummy are provided</description>
          </group>
          <group group_id="O2">
            <title>Phenazopyridine</title>
            <description>Patients receiving phenazopyridine
Phenazopyridine</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Participant-reported Pain From Pre to Post Procedure Using the Visual Analog Scale (VAS)</title>
          <description>To determine if the phenazopyridine has an analgesic effect after the retropubic midurethral slings, participants will be asked to self-report pain intensity preoperatively and then postoperatively (2 to 3 hours post procedure) using the Visual Analog Scale (VAS). The scale of the VAS is from 0 meaning &quot;no pain&quot; to 10 indicating the &quot;worst pain.&quot; The resulting change is measured as the difference between the self-reported preoperative pain score and the postoperative pain score.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="1.31"/>
                    <measurement group_id="O2" value="1.21" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to six weeks postoperatively</time_frame>
      <group_list>
        <group group_id="E1">
          <title>no Phenazopyridine</title>
          <description>Patients not receiving phenazopyridine (standard of care)
no Phenazopyridine: Because the obvious effects on the urine coloration of pyridium no placebo or dummy are provided</description>
        </group>
        <group group_id="E2">
          <title>Phenazopyridine</title>
          <description>Patients receiving phenazopyridine
Phenazopyridine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael K Flynn</name_or_title>
      <organization>University of Massachusetts UMass Memorial</organization>
      <phone>(508) 856-5152</phone>
      <email>michael.flynn@umassmemorial.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

